Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT04519476
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04421378
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, California, United States
🇺🇸University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles, California, United States
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 141
- Registration Number
- NCT04414475
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇬🇷Theageneion Cancer Hospital, Thessaloniki, Greece
🇮🇱Rabin Medical Center (Beilinson Hospital), Petah Tikva, Israel
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT04355676
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 190
- Registration Number
- NCT04349098
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT04216329
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
- Conditions
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 30
- Registration Number
- NCT04138381
- Locations
- 🇪🇸
Hospital Virgen del Rocio, Sevilla, Andalucia, Spain
🇪🇸H Vall d'Hebrón, Barcelona, Catalonia, Spain
🇪🇸Hospital Virgen de la Arrixaca, Murcia, Spain
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Sanjay Mohan
- Target Recruit Count
- 78
- Registration Number
- NCT03955783
- Locations
- 🇺🇸
Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Antengene Corporation
- Target Recruit Count
- 82
- Registration Number
- NCT03944057
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, China
🇨🇳The Third Xiangya Hospital of Central Suoth University, Changsha, Hunan, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Matthew Ingham
- Registration Number
- NCT03880123
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.